Outcomes following lung transplantation for interstitial lung diseases in New Zealand: a retrospective review

IF 1.5 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Internal Medicine Journal Pub Date : 2025-07-12 DOI:10.1111/imj.70147

Jeong Suk Oh, James Rance, Eun Ho Choe, Tanya J McWilliams, Mark O'Carroll, Christopher Lewis, Sasiharan Sithamparanathan

{"title":"Outcomes following lung transplantation for interstitial lung diseases in New Zealand: a retrospective review","authors":"Jeong Suk Oh, James Rance, Eun Ho Choe, Tanya J McWilliams, Mark O'Carroll, Christopher Lewis, Sasiharan Sithamparanathan","doi":"10.1111/imj.70147","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Interstitial lung diseases (ILDs) are a heterogeneous group of diseases that have limited treatment options and can lead to progressive respiratory failures. Lung transplantation offers a therapeutic option for selected patients. There are no New Zealand data published regarding outcomes of those who received lung transplantation for ILDs.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>We assessed survival outcomes after lung transplantation for ILDs in New Zealand, comparing bilateral versus single-lung transplants and size-matched versus mismatched lungs.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective, single-centre study included ILD patients who underwent lung transplantation from December 2006 to March 2023. Baseline characteristics, survival and post-transplant complications were analysed. Size matching was based on predicted total lung capacity ratios.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Fourty-four patients underwent lung transplantation for ILDs during this period, with a median recipient age of 54 years old. Median survival was 6.2 years; 30-day and 1-, 3-, 5- and 7-year survival rates were 84%, 80%, 66%, 58% and 49% respectively. Survival did not differ between bilateral and single lung transplants (<i>P</i> = 0.42) or between size matched and mismatched transplants (<i>P</i> = 0.58). Single lung transplants had shorter intensive care unit (ICU) stays and less intra-operative cardiopulmonary bypass use.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Lung transplantation for ILDs in New Zealand achieves survival outcomes comparable to international centres. No significant survival differences were found between bilateral and single-lung transplants or between sizes matched and mismatched lungs. Single-lung transplantation may offer advantages such as shorter ICU stays and reduced cardiopulmonary bypass use. Careful patient selection, especially in older patients, may improve outcomes.</p>\n </section>\n </div>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":"55 9","pages":"1532-1540"},"PeriodicalIF":1.5000,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imj.70147","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/ftr/10.1111/imj.70147","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Interstitial lung diseases (ILDs) are a heterogeneous group of diseases that have limited treatment options and can lead to progressive respiratory failures. Lung transplantation offers a therapeutic option for selected patients. There are no New Zealand data published regarding outcomes of those who received lung transplantation for ILDs.

Aims

We assessed survival outcomes after lung transplantation for ILDs in New Zealand, comparing bilateral versus single-lung transplants and size-matched versus mismatched lungs.

Methods

A retrospective, single-centre study included ILD patients who underwent lung transplantation from December 2006 to March 2023. Baseline characteristics, survival and post-transplant complications were analysed. Size matching was based on predicted total lung capacity ratios.

Results

Fourty-four patients underwent lung transplantation for ILDs during this period, with a median recipient age of 54 years old. Median survival was 6.2 years; 30-day and 1-, 3-, 5- and 7-year survival rates were 84%, 80%, 66%, 58% and 49% respectively. Survival did not differ between bilateral and single lung transplants (P = 0.42) or between size matched and mismatched transplants (P = 0.58). Single lung transplants had shorter intensive care unit (ICU) stays and less intra-operative cardiopulmonary bypass use.

Conclusion

Lung transplantation for ILDs in New Zealand achieves survival outcomes comparable to international centres. No significant survival differences were found between bilateral and single-lung transplants or between sizes matched and mismatched lungs. Single-lung transplantation may offer advantages such as shorter ICU stays and reduced cardiopulmonary bypass use. Careful patient selection, especially in older patients, may improve outcomes.

查看原文本刊更多论文

新西兰间质性肺疾病肺移植后的预后：回顾性回顾

背景：间质性肺疾病（ILDs）是一种异质性疾病，治疗方案有限，可导致进行性呼吸衰竭。肺移植为选定的患者提供了一种治疗选择。新西兰没有关于因ild接受肺移植的患者结果的公布数据。目的：我们评估了新西兰ild患者肺移植后的生存结果，比较了双肺移植与单肺移植以及大小匹配与不匹配的肺。方法：一项回顾性、单中心研究纳入了2006年12月至2023年3月间接受肺移植的ILD患者。分析基线特征、生存和移植后并发症。大小匹配是基于预测的总肺活量比。结果：在此期间，44例患者因ild接受了肺移植，中位受体年龄为54岁。中位生存期为6.2年；30天、1年、3年、5年、7年生存率分别为84%、80%、66%、58%、49%。双侧和单侧肺移植的生存率无差异（P = 0.42），大小匹配和不匹配移植的生存率无差异（P = 0.58）。单肺移植患者重症监护病房（ICU）住院时间较短，术中体外循环使用较少。结论：新西兰肺移植患者的生存结果与国际中心相当。双肺移植和单肺移植以及肺大小匹配和不匹配之间的生存率无显著差异。单肺移植可能具有缩短ICU住院时间和减少体外循环使用等优点。仔细选择患者，尤其是老年患者，可能会改善预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Internal Medicine Journal 医学-医学：内科

CiteScore

3.50

自引率

4.80%

发文量

600

审稿时长

3-6 weeks

期刊介绍： The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.